Qualigen, Inc. was determined to be the accounting
acquirer in a reverse recapitalization based upon the terms of the merger and other factors. All references to financial figures
of the Company presented in the accompanying consolidated financial statements and in these Notes through May 22, 2020 are to
those of Qualigen, Inc. All references to financial figures after May 22, 2020 are to those of Qualigen Therapeutics, Inc.
and Qualigen, Inc.
Property
and Equipment, Net
Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line
basis over the estimated useful lives of the related assets as follows:
|
Machinery
and equipment
|
5
years
|
|
Computer
equipment
|
3
years
|
|
Molds
and tooling
|
5
years
|
|
Office
furniture and equipment
|
5
years
|
Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company
occasionally designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other
direct costs attributable to the construction, are capitalized as construction in progress. No provision for depreciation is made
on construction in progress until the relevant assets are completed and placed in service.
The
Company’s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or
when conditions are present that indicate impairment.
Intangible
Assets, Net
Intangibles
consist of patent-related costs and costs for license agreements. Management reviews the carrying value of intangible assets that
are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that
impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized
can be recovered.
If
the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of
such intangible assets as impaired and reduces them by a charge to operations in the amount of the impairment.
Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally
5 to 17 years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent
has been obtained. Patent and licenses costs are charged to operations if it is determined that the patent will not be obtained.
The
carrying value of the patents of approximately $169,000 and $422,000 at December 31, 2020 and March 31, 2020, respectively,
are stated net of accumulated amortization of approximately $303,000 and $293,000, respectively. Amortization of patents
charged to operations for the nine months ended December 31, 2020 and year ended March 31, 2020 were approximately $10,000
and $13,000, respectively. Total future estimated amortization of patent costs for the five succeeding years is approximately
$14,000 for the year ending December 31, 2021, approximately $15,000 for each of the years ending December 31, 2022 through 2023,
approximately $14,000 for year 2024, approximately $11,000 for year 2025 and approximately $100,000 thereafter.
The
carrying value of the licenses of approximately $19,000 and $149,000 at December 31, 2020 and March 31, 2020 are stated
net of accumulated amortization of approximately $400,000 and $395,000, respectively. Amortization of licenses charged to operations
for the nine months ended December 31, 2020 and year ended March 31, 2020 was approximately $5,000, and $7,000, respectively.
Total future estimated amortization of license costs for the five succeeding years is approximately $4,000 for each of the years
ending December 31, 2021 through 2025.
Derivative
Financial Instruments and Warrant Liabilities
The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or
contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities,
the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in
the fair value reported in the Consolidated Statements of Operations. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments
at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments
should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 8).
Fair
value measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier
fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses
and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable
inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy
as follows:
|
●
|
Level
1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability
to access at the measurement date;
|
|
●
|
Level
2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including
inputs in markets that are not considered to be active; and
|
|
●
|
Level
3 - Inputs that are unobservable.
|
Fair
Value of Financial Instruments
Cash
and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt are carried at cost, which management
believes approximates fair value due to the short-term nature of these instruments.
Stock-Based
Compensation
Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated
fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line
method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other
methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated
for the Company’s stock options could change significantly. Higher volatility and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.
Income
Taxes
Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income
tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using
different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research
and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred
taxes on the temporary differences. The components of the deferred tax asset and liability are individually classified as current
and noncurrent based on their characteristics.
Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion
or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes
in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient
taxable income in future years.
Sales
and Excise Taxes
Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable
with corresponding tax payable. These balances are removed from the balance sheet as cash is collected from customers and remitted
to the tax authority.
Warranty
Costs
The
Company’s warranty policy generally provides for one year of coverage against defects and nonperformance within published
specifications for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated
warranty costs in the period in which the revenue is recognized based on historical data and the Company’s best estimates
of analyzer failure rates and costs to repair.
Accrued
warranty liabilities were approximately $25,000 and $30,000, respectively, at December 31, 2020 and March 31, 2020 and are included
in accrued expenses and other current liabilities on the balance sheets. Warranty costs were approximately $54,000 and
$57,000 for the nine months ended December 31, 2020 and year ended March 31, 2020, respectively, and are included in cost
of product sales in the statements of operations.
Recent
Accounting Pronouncements
In
June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Measurement of Credit Losses
on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when it is probable
that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial
assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition of allowances
for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU
No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases
(Topic 842), which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December
15, 2022. The new standard will be effective for the Company in the first quarter of fiscal year beginning January 1, 2023, and
early adoption is permitted. The Company has not completed its review of the impact of this standard on its consolidated financial
statements. However, based on the Company’s history of immaterial credit losses from trade receivables, management does
not expect that the adoption of this standard will have a material effect on the Company’s consolidated financial statements.
In
August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with
Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”),
which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.
ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception
and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for the Company for
fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted,
but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company’s
annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and
related disclosures.
In
May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“Topic 606”).
The guidance in Topic 606 provides that an entity should recognize revenue to depict the transfer of goods or services provided
and establishes the following steps to be applied by an entity: (1) identify the contract with a customer; (2) identify the performance
obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations
in the contract; and (5) recognize revenue when (or as) the entity satisfies the performance obligation. Topic 606 will be effective
for fiscal years beginning after December 15, 2019 for the Company, based on the issuance of ASU 2020-05, which provided deferral
of the effective date for an additional one year in response to the coronavirus (COVID-19) pandemic. The Company adopted the new
revenue standard as of April 1, 2020 using the modified retrospective approach. The adoption of ASU 2014-09/Topic 606 did not
have a material impact on the Company’s consolidated financial statements.
In
July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842) Targeted Improvements (“Topic 842”), which provides
for an alternative transition method by allowing companies to continue to use the legacy guidance in Topic 840, Leases, including
its disclosure requirements, in the comparative periods presented in the year of adoption of the new leases standard and recognize
a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption rather than the earliest
period presented. The Company adopted the standard as of April 1, 2020 and the most significant impact was the recognition of
a ROU asset and lease liability for the Company’s sole operating lease—the Company had no finance leases. Adoption
of the Topic 842 did not require the Company to restate previously reported results as it elected to apply a modified retrospective
approach at the beginning of the period of adoption rather than at the beginning of the earliest comparative period presented.
In August 2018, the FASB issued ASU No.
2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for
Fair Value Measurement,” an amendment to the accounting guidance on fair value measurements. The guidance modifies the
disclosure requirements on fair value measurements, including the removal of disclosures of the amount of and reasons for transfers
between Level 1 of the fair value hierarchy, the policy for timing of transfers between levels, and the valuation processes for
Level 3 fair value measurements. The guidance also adds certain disclosure requirements related to Level 3 fair value measurements.
The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.
The Company adopted ASU No. 2018-13 on April 1, 2020 and the adoption of this guidance did not have a material impact on its financial
statements.
Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s
consolidated financial statements.
NOTE
2 — LIQUIDITY
The
Company has incurred recurring losses from operations and has an accumulated deficit at December 31, 2020, and the Company expects
to continue to incur losses subsequent to the balance sheet date of December 31, 2020. The Company’s reverse recapitalization
transaction with Ritter closed in May 2020 together with an associated new equity capital raise of approximately $4.0 million,
and approximately $1.9 million in convertible notes payable were converted into shares of the Company’s capital stock. In
July, August and December 2020, the Company raised an additional $30.0 million through three Securities Purchase Agreements with
a single institutional investor (see Note 11). Based on the Company’s current cash position, and assuming currently planned
expenditures and level of operations, the Company believes the Company has sufficient capital to fund operations for the 12-month
period subsequent to the issuance of the accompanying consolidated financial statements. However, there is no assurance that profitable
operations will ever be achieved, or if achieved, could be sustained on a continuing basis. Also, beyond such 12-month period,
planned research and development activities, capital expenditures, clinical and pre-clinical testing, and commercialization activities
of the Company’s products are expected to require significant additional financing. Additional financing may not be available
on acceptable terms or at all.
NOTE
3 — INVENTORY, NET
Inventory,
net consisted of the following at December 31, 2020 and March 31, 2020:
|
|
December
31, 2020
|
|
|
March
31, 2020
|
|
Raw materials
|
|
$
|
579,765
|
|
|
$
|
457,425
|
|
Work in process
|
|
|
309,826
|
|
|
|
117,729
|
|
Finished goods
|
|
|
63,867
|
|
|
|
84,984
|
|
|
|
$
|
953,458
|
|
|
$
|
660,138
|
|
NOTE
4 — PREPAID EXPENSES
Prepaid
expenses consisted of the following at December 31, 2020 and March 31, 2020:
|
|
December
31, 2020
|
|
|
March
31, 2020
|
|
Prepaid insurance
|
|
$
|
1,307,864
|
|
|
$
|
26,981
|
|
Prepaid manufacturing expenses
|
|
|
1,181,029
|
|
|
|
34,078
|
|
Prepaid investor relations expenses
|
|
|
150,000
|
|
|
|
—
|
|
Other prepaid
expenses
|
|
|
40,001
|
|
|
|
37,326
|
|
|
|
$
|
2,678,894
|
|
|
$
|
98,385
|
|
NOTE
5 — PROPERTY AND EQUIPMENT, NET
Property
and equipment, net consisted of the following at December 31, 2020 and March 31, 2020:
|
|
December
31, 2020
|
|
|
March
31, 2020
|
|
Machinery and equipment
|
|
$
|
2,401,470
|
|
|
$
|
2,355,165
|
|
Construction in progress–equipment
|
|
|
104,400
|
|
|
|
1,376,000
|
|
Computer equipment
|
|
|
443,865
|
|
|
|
420,552
|
|
Leasehold improvements
|
|
|
321,033
|
|
|
|
307,539
|
|
Molds and tooling
|
|
|
260,002
|
|
|
|
260,002
|
|
Office furniture
and equipment
|
|
|
138,699
|
|
|
|
136,275
|
|
|
|
|
3,669,469
|
|
|
|
4,855,533
|
|
Less Accumulated
depreciation
|
|
|
(3,422,146
|
)
|
|
|
(3,408,019
|
)
|
|
|
$
|
247,323
|
|
|
$
|
1,447,514
|
|
Depreciation
expense relating to property and equipment was approximately $33,000 and $61,000 for the nine months ended December 31, 2020 and
year ended March 31, 2020, respectively.
NOTE
6 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued
expenses and other current liabilities consisted of the following at December 31, 2020 and March 31, 2020:
|
|
December
31, 2020
|
|
|
March
31, 2020
|
|
Board compensation
|
|
$
|
15,091
|
|
|
$
|
—
|
|
Vacation
|
|
|
230,457
|
|
|
|
160,024
|
|
Royalties
|
|
|
491
|
|
|
|
26,099
|
|
Research and development
|
|
|
237,504
|
|
|
|
288,184
|
|
Professional fees
|
|
|
58,261
|
|
|
|
277,900
|
|
Deferred rent
|
|
|
—
|
|
|
|
77,597
|
|
Warranty costs
|
|
|
24,871
|
|
|
|
30,119
|
|
Payroll
|
|
|
4,566
|
|
|
|
35,052
|
|
Patent and license fees
|
|
|
7,204
|
|
|
|
51,007
|
|
Sales and use taxes
|
|
|
30,353
|
|
|
|
16,755
|
|
Income taxes
|
|
|
3,326
|
|
|
|
8,100
|
|
Interest
|
|
|
—
|
|
|
|
247,569
|
|
Other
|
|
|
134,614
|
|
|
|
25,358
|
|
|
|
$
|
746,738
|
|
|
$
|
1,243,764
|
|
NOTE
7 — NOTES PAYABLE
Notes
payable consisted of the following at December 31, 2020 and March 31, 2020:
|
|
December
31, 2020
|
|
|
March
31, 2020
|
|
Insurance Financing Agreement
with a finance company, monthly payments of $119,943 including interest of 4.54% per annum; secured by an insurance policy;
due January 2021
|
|
$
|
119,491
|
|
|
$
|
—
|
|
Equipment Financing Agreement with
a bank, monthly payments of $720 including imputed interest at 6.95% per annum; secured by laboratory equipment; due October
2022
|
|
|
14,826
|
|
|
|
20,370
|
|
Equipment Financing Agreement with
a bank, monthly payments of $596 including imputed interest at 6.590% per annum; secured by manufacturing equipment; due July
2021
|
|
|
4,422
|
|
|
|
9,441
|
|
A Factoring and Security Agreement
for up to $2,000,000 with a bank, interest at Prime plus 2% of the amount of advances outstanding and a factoring fee of 0.01%
per day of the face amount of each invoice for each calendar day that a factored invoice is outstanding
|
|
|
—
|
|
|
|
489,051
|
|
An unsecured convertible note with
an investor including interest at 10% per annum; due September 2019, which was extended by the noteholder until May 2020
|
|
|
—
|
|
|
|
1,000,000
|
|
A series of unsecured convertible
bridge notes with investors, including interest of 8% per annum; due between June 2020 and February 2021
|
|
|
—
|
|
|
|
410,000
|
|
A series of
unsecured convertible bridge notes with investors, including interest of 8% per annum; due between January and February 2022
|
|
|
—
|
|
|
|
290,198
|
|
|
|
|
138,739
|
|
|
|
2,219,060
|
|
Less
current portion, net of debt issuance costs
|
|
|
(131,766
|
)
|
|
|
(1,913,255
|
)
|
Notes
Payable, net of current portion
|
|
$
|
6,973
|
|
|
$
|
305,805
|
|
Future
maturities of notes payable are as follows as of December 31, 2020:
Year
Ending December 31,
|
|
Amount
|
|
2021
|
|
$
|
131,766
|
|
2022
|
|
|
6,973
|
|
Total balance
|
|
$
|
138,739
|
|
NOTE
8 – WARRANT LIABILITIES
In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection
with a private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing
of the reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant
to the Series C Warrant terms as adjusted.
In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase an aggregate
of 4,713,490 shares of the Company’s common stock at $0.72 per share, subject to adjustment. As of December 31, 2020, the
warrants received in exchange for the Series C Warrants have remaining terms ranging from 2.9 to 3.5 years. The warrants were
determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, resulting from inclusion of a leveraged
ratchet provision for subsequent dilutive issuances.
The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants for the nine months ended
December 31, 2020:
|
|
Common
Stock Warrants (received in exchange for the
Series C Warrants)
|
|
|
|
Shares
|
|
|
Weighted–
Average
Exercise
Price
|
|
|
Range
of Exercise
Price
|
|
|
Weighted–
Average
Remaining
Life (Years)
|
|
Total outstanding – March 31, 2020
|
|
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
Series
C preferred stock warrants exchanged for common stock warrants upon reverse recapitalization
|
|
|
4,713,490
|
|
|
|
0.72
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(1,334,894
|
)
|
|
|
0.72
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total outstanding – December
31, 2020
|
|
|
3,378,596
|
|
|
$
|
0.72
|
|
|
|
|
|
|
|
|
|
Exercisable
|
|
|
3,378,596
|
|
|
$
|
0.72
|
|
|
$
|
0.72
|
|
|
|
3.02
|
|
Non-Exercisable
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
—
|
|
The
following table summarizes the Series C Warrants activity for the year ended March 31, 2020:
|
|
Series
C Preferred Stock Warrants
|
|
|
|
Shares
|
|
|
Weighted–
Average
Exercise
Price
|
|
|
Range
of Exercise
Price
|
|
|
Weighted–
Average
Remaining
Life
(Years)
|
|
Total
outstanding – March 31, 2019
|
|
|
1,441,180
|
|
|
$
|
2.35
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total
outstanding – March 31, 2020
|
|
|
1,441,180
|
|
|
$
|
2.35
|
|
|
|
|
|
|
|
|
|
Exercisable
|
|
|
1,441,180
|
|
|
$
|
2.35
|
|
|
$
|
2.25 – $2.70
|
|
|
|
4.85
|
|
Non-Exercisable
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
—
|
|
The
following table summarizes the Series C Warrants activity for the nine months ended December 31, 2020:
|
|
Series
C Preferred Stock Warrants
|
|
|
|
Shares
|
|
|
Weighted–
Average
Exercise
Price
|
|
|
Range
of
Exercise
Price
|
|
|
Weighted–
Average
Remaining
Life
(Years)
|
|
Total outstanding – March 31, 2020
|
|
|
1,441,180
|
|
|
$
|
2.35
|
|
|
$
|
2.25 – $2.70
|
|
|
|
4.85
|
|
Series C preferred
stock warrants exchanged for common stock warrants upon reverse recapitalization
|
|
|
(1,441,180
|
)
|
|
|
2.35
|
|
|
|
|
|
|
|
|
|
Total outstanding – December 31, 2020
|
|
|
—
|
|
|
$
|
—
|
|
|
|
—
|
|
|
|
—
|
|
The
following table presents the Company’s fair value hierarchy for its warrant liabilities (all of which arise under the warrants
received in exchange for the Series C Warrants) measured at fair value on a recurring basis as of December 31, 2020:
|
|
Quoted
|
|
|
|
|
|
|
|
|
|
|
|
|
Market
|
|
|
Significant
|
|
|
|
|
|
|
|
|
|
Prices
for
|
|
|
Other
|
|
|
Significant
|
|
|
|
|
|
|
Identical
|
|
|
Observable
|
|
|
Unobservable
|
|
|
|
|
|
|
Assets
|
|
|
Inputs
|
|
|
Inputs
|
|
|
|
|
Warrant
liabilities
|
|
(Level
1)
|
|
|
(Level
2)
|
|
|
(Level
3)
|
|
|
Total
|
|
Balance as of December
31, 2020
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
8,310,100
|
|
|
$
|
8,310,100
|
|
There
were no transfers of financial assets or liabilities between category levels for the nine months ended December 31, 2020.
The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate
the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history
as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of
the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid
cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may
result in significantly higher or lower fair value measurements.
The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted
average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2020:
|
|
December 31, 2020
|
|
|
|
Range
|
|
|
Weighted Average
|
|
Risk-free interest rate
|
|
|
0.17%
— 0.22
|
%
|
|
|
0.18
|
%
|
Expected volatility (peer group)
|
|
|
82.00
|
%
|
|
|
82.00
|
%
|
Term of warrants (in years)
|
|
|
2.90
— 3.49
|
|
|
|
3.02
|
|
Expected dividend yield
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
The
value of the warrant liabilities is based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation.
NOTE
9 — LEASES
The
Company leases its facilities under a long-term operating lease agreement expiring in October 2022. The tables below show the
operating lease right-of-use assets and operating lease liabilities as of initial measurement at April 1, 2020 and the
balances as of December 31, 2020, including the changes during the periods:
|
|
Operating
lease
right-of-use assets
|
|
Initial measurement at April 1, 2020:
|
|
$
|
663,110
|
|
Less deferred
rent allowance
|
|
|
(77,597
|
)
|
Net right-of-use assets at April 1,
2020
|
|
|
585,513
|
|
Less amortization
of operating lease right-of-use assets
|
|
|
(154,718
|
)
|
Operating lease
right-of-use assets at December 31, 2020
|
|
$
|
430,795
|
|
|
|
Operating lease
liabilities
|
|
Initial measurement
at April 1, 2020:
|
|
$
|
663,110
|
|
Less principal
payments on operating lease liabilities
|
|
|
(171,545
|
)
|
Operating lease
liabilities at December 31, 2020
|
|
|
491,565
|
|
Less non-current
portion
|
|
|
236,826
|
|
Current portion at December 31,
2020
|
|
$
|
254,739
|
|
As
of December 31, 2020, the Company’s operating leases have a weighted-average remaining lease term of 1.8 years and a weighted-average
discount rate of 8.9%.
As
of December 31, 2020, the maturities of operating lease liabilities are as follows:
Year
Ending December 31,
|
|
Amount
|
|
2021
|
|
$
|
288,355
|
|
2022
|
|
|
246,650
|
|
Total
|
|
|
535,005
|
|
Less present
value discount
|
|
|
(43,440
|
)
|
Operating lease
liabilities
|
|
$
|
491,565
|
|
Total
lease expense was approximately $259,000 and $343,000, respectively, for the nine months ended December 31, 2020 and year ended
March 31, 2020. Lease expense was recorded in cost of product sales, general and administrative expenses, research and development
and sales and marketing expenses.
NOTE
10 — RESEARCH AND LICENSE AGREEMENTS
Between
June 2018 and September 2020, the Company entered into license and sponsored research agreements with the University of Louisville
Research Foundation (“ULRF”) for QN-247, a novel molecular-based compound that has shown promise as an anticancer
drug. Under the agreements, the Company will take over development, regulatory approval and commercialization of the compound
from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $50,000
convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common
stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to $805,000 and prior patent costs of up
to $200,000. In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization
of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above
a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty
sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF
license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution
and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the
achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be
$100,000 for first dosing in a Phase 1 clinical trial, $200,000 for first dosing in a Phase 2 clinical trial, $350,000 for first
dosing in a Phase 3 clinical trial, $500,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000
of Licensed Product sales; the Company would also pay another $500,000 milestone payment for any additional regulatory marketing
approval for each additional therapeutic (or diagnostic) indication. The Company also must pay ULRF shortfall payments if the
total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable
annual minimum (ranging from $10,000 to $50,000) for such year.
There
was approximately $14,000 and $117,000 in sponsored research expenses related to these agreements for the nine months ended December
31, 2020 and year ended March 31, 2020, respectively, and these amounts are recorded in research and development expenses in the
statements of operations. Minimum annual royalties of $10,000 and $0 related to these agreements are included in research and
development expenses in the statements of operations for the nine months ended December 31, 2020 and year ended March 31, 2020,
respectively. License costs were approximately $470,000 and $0 related to these agreements for the nine months ended
December 31, 2020 and year ended March 31, 2020, respectively, and are included in research and development expenses in the
statements of operations.
In
December 2018, the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (“ACT”), granting
the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $25,000
convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common
stock. In addition, the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165,
of 2% (only if patent-covered and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net
sales above a cumulative $3,000,000), until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $100,000
for the Company raising a cumulative total of $2,000,000 in new equity financing after the date of the ACT license agreement,
$100,000 upon any first QN-165-based licensed product receiving the CE Mark or similar FDA status, and $500,000 upon cumulative
worldwide QN-165-based licensed product net sales reaching $3,000,000. In May 2020, the $100,000 milestone payment for the Company
raising a cumulative total of $2,000,000 in new equity financing was triggered. This amount is included in research and development
expenses as of December 31, 2020. Between April and August 2020, the Company purchased drug compounds from ACT for $10,000,
and an Investigational New Drug (IND) application from ACT for an additional $100,000. Upon successful recertification of the
drug compounds, ACT will receive an additional $50,000. Of these amounts, for the nine months ended December 31, 2020 and year
ended March 31, 2020, $100,000 and $0 respectively, are included in research and development expenses in the statements of operations.
In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development
of several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company will reimburse
ULRF for sponsored research expenses of up to $693,000 for this program. In July 2020, the Company entered into an exclusive license
agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development,
regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual
property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent
costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization,
of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of
the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty
sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF
license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution
and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the
achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be
$50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first
dosing in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000
of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to
royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $20,000 to
$100,000) for such year.
Sponsored
research expenses related to these agreements for the nine months ended December 31, 2020 and year ended March 31, 2020 were approximately
$283,000 and $205,000, respectively, and are recorded in research and development expenses in the statements of operations. License
costs related to these agreements for the nine months ended December 31, 2020 and year ended March 31, 2020 were approximately
$160,000 and $0, respectively, and are included in research and development expenses in the statements of operations.
In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165
as a treatment for COVID-19. Under the agreement, the Company will take over development, regulatory approval and commercialization
of the compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In
return, ULRF received approximately $24,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the
Company was required to enter into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19)
for at least $250,000. In November 2020, the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment
for COVID-19) supporting up to approximately $430,000 in research which satisfied this requirement (see Note 13).
In
addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization
of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents),
(ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF
license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with
the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging
from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments would be $50,000
for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing
in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000
of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to
royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $5,000 to $50,000)
for such year. License costs related to this agreement for the nine months ended December 31, 2020 and year ended March 31,
2020 were approximately $24,000 and $0, respectively, and are included in research and development expenses in the statements
of operations.
In
November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS, an unrelated
party, to develop and manufacture diagnostic tests for use in the stroke point-of-care market. The Company recognizes development
revenue and product sales over the performance period of the contract. For the nine months ended December 31, 2020 and year ended
March 31, 2020, there was $0 and $85,000, respectively, in collaborative research revenue related to this agreement.
During
the year ended March 31, 2018, the Company extended a strategic partnership entered into in May 2016 with Sekisui Diagnostics,
LLC (“Sekisui”) until May 2022. The Company appointed Sekisui as its diagnostics commercial partner and exclusive
worldwide distributor with the exception of certain customer accounts retained by Qualigen. The agreement contains a right of
first refusal for Sekisui against any potential acquisition of the Company until May 2022.
There
were product sales to Sekisui of approximately $1.6 million and $3.4 million, respectively, for the nine months ended December
31, 2020 and year ended March 31, 2020, related to this agreement.
In
October 2020, the Company entered into a Technology Transfer Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (“Yi Xin”),
of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on the Company’s
core FastPack technology. In addition, the Technology Transfer Agreement authorized Yi Xin to manufacture and sell the Company’s
current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.
Under
the Technology Transfer Agreement, the Company received net cash payments of $250,000 in the final quarter of the Transition Period,
classified as deferred revenue on the December 31, 2020 balance sheet, and $420,000 in the first quarter of 2021, plus the Company
will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin.
The Company provided technology transfer and patent/know-how license rights to facilitate Yi Xin’s development and commercialization.
The
Company gave Yi Xin the exclusive rights for China – which is a market the Company has not otherwise entered – both
for Yi Xin’s new generations of FastPack-based products and for Yi Xin-manufactured versions of the Company’s existing
FastPack product lines. Yi Xin will also have the right to sell its new generations of FastPack-based diagnostic test systems
throughout the world (but not to or toward current customers of the Company’s existing generations of FastPack products);
any such non-China sales would, until May 1, 2022, need to be through Sekisui. In addition, after May 1, 2022, Yi Xin will have
the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than in the
United States and other than to or toward current non-US customers of those products). Also, after May 1, 2022, Yi Xin will have
the right to buy Company-manufactured FastPack 1.0, IP and PRO products from the Company at distributor prices for resale in and
for the United States (but not to or toward current US customers of those products); the Company did not license Yi Xin to sell
in the United States market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines, even after
May 1, 2022. In the Technology Transfer Agreement, the Company confirmed that it would not, after May 1, 2022, seek new FastPack
customers outside the United States.
In
November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production
of QN-165, the Company’s lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical
trials in 2021. In connection with this agreement, the Company paid an upfront deposit of approximately $1.1 million which is
classified as prepaid expenses on the December 31, 2020 balance sheet date.
NOTE 11 — STOCKHOLDERS’ EQUITY
(DEFICIT)
As
of December 31, 2020, the Company had two classes of capital stock: common stock and Series Alpha convertible preferred stock.
As of March 31, 2020, the Company had two classes of capital stock with one being divided into five series: common stock and preferred
stock (Series A convertible preferred stock, Series B convertible preferred stock, Series C convertible preferred stock, Series
D convertible preferred stock and Series D-1 convertible preferred stock).
Common
Stock
Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share
held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock
are entitled to receive dividends when and if declared by the Board of Directors. Following payment of the liquidation preference
of the preferred stock, as of March 31, 2020 any remaining assets would be distributed ratably among the holders of the common
stock and, on an as-if-converted basis, the holders of Series C convertible preferred stock, Series D convertible preferred stock
and Series D-1 convertible preferred stock) upon liquidation, dissolution or winding up of the affairs of the Company. Following
payment of the liquidation preference of the preferred stock, as of December 31, 2020 any remaining assets would be distributed
ratably among the holders of the common stock and, on an as-if-converted basis, the holders of Series Alpha convertible preferred
stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.
At
December 31, 2020, the Company has reserved 15,477,364 shares of authorized but unissued common stock for possible future issuance.
At December 31, 2020, shares were reserved in connection with the following:
Exercise of issued and future
grants of stock options
|
|
|
4,011,356
|
|
Exercise of stock warrants
|
|
|
11,222,590
|
|
Conversion of
Series Alpha preferred stock
|
|
|
243,418
|
|
Total
|
|
|
15,477,364
|
|
Series
A, B, C, D, D-1, Alpha Convertible Preferred Stock
At
March 31, 2020, there were 2,412,887, 7,707,736, 3,300,715, 1,508,305 and 643,511 shares of Series A, B, C, D, D-1 convertible
preferred stock outstanding respectively. All shares of Series A, B, C, D, D-1 convertible preferred stock were converted into
common stock at the time of the May 2020 reverse recapitalization transaction.
In
the nine months ended December 31, 2020, the holder of Series Alpha preferred stock converted 5,180 of its shares of Series Alpha
preferred stock into an aggregate of 7,004,983 shares of the Company’s common stock, and there were 180 shares of Series
Alpha preferred stock outstanding at December 31, 2020.
Alpha
Securities Purchase Agreements
On
July 10, 2020, the Company closed a Securities Purchase Agreement (dated July 8, 2020) with a single institutional investor for
the purchase and sale for $8.0 million for (i) 1,140,570 shares of Company common stock, (ii) 780,198 pre-funded warrants (i.e.,
warrants to purchase shares of Company common stock, for which the exercise price is almost entirely prepaid) and (iii) 1,920,768
two-year warrants to purchase shares of Company common stock for an exercise price of $5.25 per share. Both sets of warrants included
a 9.99% beneficial-ownership blocker provision. The 780,198 pre-funded warrants were then exercised on July 21 and 22, 2020.
On
August 4, 2020, the Company closed a Securities Purchase Agreement (dated August 2, 2020) with a single institutional investor
for the purchase and sale for $10.0 million for (i) 1,717,106 shares of Company common stock, and (ii) 1,287,829 two-year warrants
to purchase shares of Company common stock for an exercise price of $6.00 per share. The warrants included a 9.99% beneficial-ownership
blocker provision.
On
December 18, 2020, the Company closed a Securities Purchase Agreement (dated December 16, 2020) with a single institutional investor
for the purchase and sale for $12,000,000 of (i) 2,370,786 shares of Company common stock, (ii) 1,000,000 pre-funded warrants
(i.e., warrants to purchase shares of Company common stock, for which the exercise price is almost entirely prepaid) (iii) 1,348,314
two-year warrants to purchase shares of Company common stock for an exercise price of $4.07 per share, and (iv) 842,696 warrants
(first exercisable 6 months after issuance, and with an expiration date 30 months after issuance) to purchase shares of Company
common stock for an exercise price of $4.07 per share. The warrants included a 9.99% beneficial-ownership blocker provision.
Stock
Options and Equity Classified Warrants
Stock
Options
The
Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the
vesting period.
In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”) which provides for the granting of
incentive or nonstatutory common stock options to qualified employees, officers, directors, consultants and other service providers.
At December 31, 2020 and March 31, 2020 there were 3,917,500 and 0 outstanding options respectively under the 2020 Plan and there
were 139,657 and 0 options available respectively for future grant.
The
following represents a summary of the options granted to employees and non-employee service providers that are outstanding at
December 31, 2020, and changes during the nine months then ended:
|
|
Shares
|
|
|
Weighted–
Average
Exercise
Price
|
|
|
Range
of
Exercise
Price
|
|
|
Weighted–
Average
Remaining
Life
(Years)
|
|
Total outstanding – March 31,
2020
|
|
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
Legacy
Ritter options
|
|
|
95,124
|
|
|
|
92.80
|
|
|
$
|
5.75—$1,465.75
|
|
|
|
1.39
|
|
Granted
|
|
|
3,917,500
|
|
|
|
4.97
|
|
|
$
|
3.52—$5.13
|
|
|
|
9.46
|
|
Expired
|
|
|
(1,268
|
)
|
|
|
34.54
|
|
|
$
|
15.00
— 562.50
|
|
|
|
|
|
Forfeited
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total outstanding – December
31, 2020
|
|
|
4,011,356
|
|
|
$
|
7.05
|
|
|
$
|
3.52—$1,465.75
|
|
|
|
9.29
|
|
Exercisable (vested)
|
|
|
108,856
|
|
|
$
|
81.38
|
|
|
$
|
3.52—$1,465.75
|
|
|
|
2.50
|
|
Non-Exercisable
(non-vested)
|
|
|
3,902,500
|
|
|
$
|
4.97
|
|
|
$
|
3.52—$5.13
|
|
|
|
9.47
|
|
There
was approximately $2.8 million and $0 of compensation costs related to outstanding options for the nine months ended December
31, 2020 and year ended March 31, 2020, respectively. As of December 31, 2020, there was approximately $12.6 million of total
unrecognized compensation cost related to unvested stock-based compensation arrangements. This cost is expected to be recognized
over a weighted average period of 2.46 years.
No
stock options were exercised during the nine months ended December 31, 2020.
The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of
an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than
110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair
market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair
market value per share on the date of grant. The options awarded under the 2020 Plan will vest as determined by the Board of Directors
but will not exceed a ten-year period. The weighted average grant date fair value per share of the shares underlying options granted
during the nine months ended December 31, 2020 was $4.97.
Fair
Value of Equity Awards
The
Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan. Key valuation assumptions include:
●
|
Expected
dividend yield. The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current
plans to pay any dividends on the Company’s common stock.
|
|
|
●
|
Expected
stock-price volatility. The Company’s expected volatility is derived from the average historical volatilities of
publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s
business over a period approximately equal to the expected term.
|
|
|
●
|
Risk-free
interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero
coupon U.S. Treasury notes with maturities approximately equal to the expected term.
|
|
|
●
|
Expected
term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s
historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because
of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by
the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life
of the options.
|
The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:
|
|
For
the nine
months
ended
December
31, 2020
|
|
Expected dividend yield
|
|
|
0.00
|
%
|
Expected stock-price volatility
|
|
|
102
|
%
|
Risk-free interest rate
|
|
|
0.33%
— 0.65
|
%
|
Expected average term of options (in
years)
|
|
|
6.0
|
|
Stock price
|
|
$
|
3.52 — 5.13
|
|
The
Company recorded stock-based compensation expense and classified it in the consolidated statements of operations as follows:
|
|
For
the nine months
ended
December
31, 2020
|
|
|
For
the year
ended
March
31, 2020
|
|
General and administrative
|
|
$
|
2,388,380
|
|
|
$
|
4,830
|
|
Research and
development
|
|
|
412,471
|
|
|
|
3,036
|
|
Total
|
|
$
|
2,800,851
|
|
|
$
|
7,866
|
|
Equity
Classified Compensatory Warrants
In
the nine months ended December 31, 2020, in connection with the $4.0 million equity capital raise as part of the May 2020 reverse
recapitalization transaction, the Company issued common stock warrants to an advisor and its designees for the purchase of 811,431
shares of the Company’s common stock at an exercise price of $1.11 per share. The issuance cost of these warrants was charged
to additional paid-in capital, and did not result in expense on the Company’s statements of operations.
In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable
to purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of 668,024
shares of Company common stock at a weighted average exercise price of $2.34 per share. These are to be differentiated from the
Series C Warrants described in Note 8.
No
compensatory warrants were issued in the year ended March 31, 2020.
The
following table summarizes the equity classified compensatory warrant activity for the nine months ended December 31, 2020:
|
|
Common
Stock
|
|
|
|
Shares
|
|
|
Weighted–
Average
Exercise
Price
|
|
|
Range
of
Exercise Price
|
|
|
Weighted–
Average
Remaining
Life
(Years)
|
|
Total outstanding – March 31, 2020
|
|
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
Series
C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization
|
|
|
668,024
|
|
|
|
2.25
|
|
|
|
|
|
|
|
|
|
Granted
to advisor and its designees
|
|
|
811,431
|
|
|
|
1.11
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(159,978
|
)
|
|
|
1.26
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(25,260
|
)
|
|
|
2.07
|
|
|
|
|
|
|
|
|
|
Total outstanding
– December 31, 2020
|
|
|
1,294,217
|
|
|
$
|
1.6670
|
|
|
|
|
|
|
|
|
|
Exercisable
|
|
|
1,290,621
|
|
|
$
|
1.66
|
|
|
$
|
1.11 —$2.54
|
|
|
|
4.17
|
|
Non-Exercisable
|
|
|
3,596
|
|
|
$
|
2.54
|
|
|
$
|
2.54
|
|
|
|
5.72
|
|
The
following table summarizes the compensatory warrant activity for the year ended March 31, 2020:
|
|
Series
C Preferred Stock Warrants
|
|
|
|
Shares
|
|
|
Weighted–
Average
Exercise
Price
|
|
|
Range
of
Exercise Price
|
|
|
Weighted–
Average
Remaining
Life
(Years)
|
|
Total outstanding – March 31, 2019
|
|
|
756,262
|
|
|
$
|
1.99
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(2,000
|
)
|
|
|
2.25
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total outstanding – March
31, 2020
|
|
|
754,262
|
|
|
$
|
1.99
|
|
|
|
|
|
|
|
|
|
Exercisable
|
|
|
746,142
|
|
|
$
|
1.99
|
|
|
$
|
1.83
– $2.25
|
|
|
|
4.59
|
|
Non-Exercisable
|
|
|
8,120
|
|
|
$
|
2.25
|
|
|
$
|
2.25
|
|
|
|
6.48
|
|
There
were no compensation costs related to outstanding warrants for the nine months ended December 31, 2020 and year ended March 31,
2020. As of December 31, 2020 and March 31, 2020, there was no unrecognized compensation cost related to nonvested warrants.
Noncompensatory
Equity Classified Warrants
In
the nine months ended December 31, 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to
an investor for the purchase of 270,478 shares of Company common stock at an exercise price of $1.11 per share. In addition, in
July 2020 the Company issued noncompensatory equity classified warrants to an investor for the purchase of 2,700,966 shares of
Company common stock at an exercise price of $5.25 per share, and in August 2020 the Company issued noncompensatory equity classified
warrants to such investor for the purchase of 1,287,829 shares of Company common stock at an exercise price of $6.00 per share.
Lastly, in December 2020, the Company issued noncompensatory equity classified warrants to such investor for the purchase of 1,000,000
shares of Company common stock at an exercise price of $0.01 per share and 2,191,000 shares of Company common stock at an exercise
price of $4.07 per share. No noncompensatory equity classified warrants were issued in the year ended March 31, 2020.
The
following table summarizes the noncompensatory equity classified warrant activity for the nine months ended December 31, 2020:
|
|
Common
Stock
|
|
|
|
Shares
|
|
|
Weighted–
Average
Exercise
Price
|
|
|
Range
of
Exercise
Price
|
|
|
Weighted–
Average
Remaining
Life
(Years)
|
|
Total outstanding – March 31, 2020
|
|
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
Legacy
Ritter warrants
|
|
|
81,455
|
|
|
|
21.94
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
7,450,193
|
|
|
|
4.18
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(980,198
|
)
|
|
|
1.11
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
(1,673
|
)
|
|
|
1,562.50
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total outstanding – December
31, 2020
|
|
|
6,549,777
|
|
|
$
|
4.36
|
|
|
|
|
|
|
|
|
|
Exercisable
|
|
|
5,707,081
|
|
|
$
|
4.40
|
|
|
$
|
0.01
– $2,325.00
|
|
|
|
1.43
|
|
Non-Exercisable
|
|
|
842,696
|
|
|
$
|
4.07
|
|
|
|
4.07
|
|
|
|
3.00
|
|
NOTE
12 — INCOME TAXES
A
reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows:
|
|
December
31, 2020
|
|
|
March
31, 2020
|
|
Statutory federal income
tax rate
|
|
|
21.0
|
%
|
|
|
21.0
|
%
|
State taxes, net of federal tax benefit
|
|
|
2.5
|
%
|
|
|
2.0
|
%
|
Non-deductible expenses
|
|
|
(0.5
|
)%
|
|
|
(0.2
|
)%
|
Tax credit
|
|
|
(2.8
|
)%
|
|
|
7.1
|
%
|
Change in fair value of warrant liability
|
|
|
(8.9
|
)%
|
|
|
—
|
%
|
True-up
|
|
|
(1.1
|
)%
|
|
|
(7.6
|
)%
|
Change in valuation
allowance
|
|
|
(10.3
|
)%
|
|
|
(22.6
|
)%
|
Income taxes
provision
|
|
|
(0.1
|
)%
|
|
|
(0.3
|
)%
|
Income
tax expense for the nine months ended December 31, 2020 and year ended March 31, 2020 consisted of the following:
|
|
December 31, 2020
|
|
|
March 31, 2020
|
|
Current
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
—
|
|
|
$
|
—
|
|
State
|
|
|
1,000
|
|
|
|
4,000
|
|
Total current provision
|
|
|
1,000
|
|
|
|
4,000
|
|
Deferred
|
|
|
|
|
|
|
|
|
Federal
|
|
|
(1,634,000
|
)
|
|
|
(346,000
|
)
|
State
|
|
|
(384,000
|
)
|
|
|
(55,000
|
)
|
Total deferred benefit
|
|
|
(2,018,000
|
)
|
|
|
(401,000
|
)
|
Change in valuation allowance
|
|
|
2,017,000
|
|
|
|
401,000
|
|
Total provision for income taxes
|
|
$
|
—
|
|
|
$
|
4,000
|
|
The
components of deferred tax assets and liabilities are as follows:
|
|
December 31, 2020
|
|
|
March 31, 2020
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Net operating loss
|
|
$
|
28,914,000
|
|
|
$
|
8,127,000
|
|
Research and development credits
|
|
|
5,464,000
|
|
|
|
2,012,000
|
|
Accrued expenses
|
|
|
292,000
|
|
|
|
348,000
|
|
Patent
|
|
|
422,000
|
|
|
|
—
|
|
Impairment loss
|
|
|
361,000
|
|
|
|
—
|
|
Stock compensation
|
|
|
2,654,000
|
|
|
|
—
|
|
Other
|
|
|
84,000
|
|
|
|
56,000
|
|
Total deferred income tax assets
|
|
|
38,191,000
|
|
|
|
10,543,000
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Fixed assets
|
|
|
44,000
|
|
|
|
(9,000
|
)
|
Intangible assets
|
|
|
(18,000
|
)
|
|
|
(22,000
|
)
|
Total deferred income tax liabilities
|
|
|
26,000
|
|
|
|
(31,000
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred income tax assets
|
|
|
38,217,000
|
|
|
|
10,512,000
|
|
Valuation allowance
|
|
|
(38,217,000
|
)
|
|
|
(10,512,000
|
)
|
Net deferred tax asset
|
|
$
|
—
|
|
|
$
|
—
|
|
Based
on the available objective evidence, including the Company’s history of cumulative losses, management believes it is likely
that the net deferred tax assets will not be realizable. Accordingly, the Company provided for a full valuation allowance against
its net deferred tax assets at December 31, 2020 and March 31, 2020.
At
December 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $111,400,000 and
$82,500,000, respectively, which are available to offset future taxable income. Federal and State carryovers began to expire
in 2019. As a result of the May 2020 reverse recapitalization an ownership change has occurred. The Company has not completed
an Internal Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company’s ability
to utilize its pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result
in both a permanent loss of certain tax benefits related to net operating loss carryforwards and federal research and development
credits, and an annual utilization limitation. Due to the full valuation allowance already in place, the Company does not anticipate
any change in the Company’s effective tax rate.
The
Company also has research and development credit carryforwards for federal and state tax purposes of approximately $3,800,000
and $1,700,000, respectively. The research and development credit carryforwards began to expire in 2019 for federal tax purposes
and have an indefinite life for state tax purposes.
The
Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company’s federal income tax
returns for the years 2016 and beyond remain subject to examination by the Internal Revenue Service. The Company’s California
income tax returns for the years 2015 and beyond remain subject to examination by the California Franchise Tax Board. In addition,
all of the net operating losses, research and development credit and other tax credit carryforwards that may be used in future
years are still subject to adjustment.
Generally
accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company’s financial
statements and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to
be taken in a tax return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be
taken in a tax return. The Company adopted these provisions effective April 1, 2009.
The
Company did not have any unrecognized tax benefits as of December 31, 2020 and March 31, 2020 and does not expect this to change
significantly over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize
interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2020,
the Company has not accrued any interest or penalties related to uncertain tax positions.
NOTE
13 — RELATED PARTY TRANSACTIONS
In
October 2017, Sekisui purchased all outstanding shares of the Company’s Series D and Series D-1 preferred stock from Gen-Probe
Incorporated. As such, Sekisui became a related party as of October 2017. These Series D and Series D-1 preferred stock shares
were converted into 1,980,233 shares of the Company’s common stock in connection with the reverse recapitalization transaction
in May 2020. However, during the nine months ended December 31, 2020, Sekisui ceased to be a related party, so sales to (and costs
related to sales to) Sekisui will not be classified as “related party” line items in our 2021 statement of operations.
The
following are transactions made between the Company and Sekisui as of and for the nine months ended December 31, 2020 and year
ended March 31, 2020:
|
●
|
The
Company sells products and provides collaborative research and development (“R&D”) services to Sekisui.
As of December 31, 2020 and March 31, 2020, the Company had a receivable from Sekisui of approximately $381,000 and $290,000,
respectively. The Company recorded product sales to Sekisui of approximately $1.6 million and $3.4 million for the nine months
ended December 31, 2020 and year ended March 31, 2020, respectively. In May 2019, the Company and Sekisui terminated the R&D
portion of their distribution and development agreement. There was no collaborative R&D revenue from Sekisui for the nine
months ended December 31, 2020 and year ended March 31, 2020. The Company had cost of product sales relating to Sekisui of
approximately $1.7 million and $2.5 million for the nine months ended December 31, 2020 and year ended March 31, 2020, respectively.
R&D expenses relating to Sekisui were approximately $0 and $525,000 for the nine months ended December 31, 2020 and year
ended March 31, 2020, respectively.
|
|
|
|
|
●
|
As
of December 31, 2020 and March 31, 2020, the Company had approximately $0 and $0.9 million, respectively, classified as due
to related party (Sekisui) on the accompanying balance sheets. The Company satisfied the $0.9 million obligation which existed
at March 31, 2020 (related to product development financing payments made by Sekisui) by payment in full on July 21, 2020.
|
|
|
|
|
●
|
As
of December 31, 2020 and March 31, 2020, the Company had approximately $95,000 and $271,000 classified as deferred revenue
from Sekisui on the accompanying balance sheets, respectively.
|
NOTE
14 — TRANSITION PERIOD COMPARATIVE DATA
The
following table presents certain comparative transition period financial information for the nine months ended December 31, 2020
and 2019, respectively.
|
|
Nine Months Ended December 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
|
|
|
(Unaudited)
|
|
Revenues
|
|
$
|
2,849,561
|
|
|
$
|
4,101,212
|
|
Gross profit
|
|
$
|
209,413
|
|
|
$
|
1,114,834
|
|
Net loss before income taxes
|
|
$
|
(19,546,366
|
)
|
|
$
|
(910,317
|
)
|
Net loss
|
|
$
|
(19,546,366
|
)
|
|
$
|
(911,900
|
)
|
Net loss per share – basic and fully diluted
|
|
$
|
(1.12
|
)
|
|
$
|
(0.16
|
)
|
Weighted average shares used in computing basic and diluted net loss per share
|
|
|
17,431,714
|
|
|
|
5,602,214
|
|
NOTE
15 — SUBSEQUENT EVENTS
In
February 2021, the Company extended its sponsored research agreement with ULRF for development of several small-molecule RAS interaction
inhibitor drug candidates and increased the amount that the Company will reimburse ULRF for sponsored research expenses from $693,000
to approximately $1.4 million (see Note 10).